Cargando…

Could Early Anti-Tumor Necrosis Factor Therapy Change the Prognosis of Crohn's Disease?

Detalles Bibliográficos
Autor principal:	Ye, Byong Duk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2014
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214950/ https://www.ncbi.nlm.nih.gov/pubmed/25374489 http://dx.doi.org/10.5217/ir.2014.12.4.263

Ejemplares similares

Patients’ Preference for a Specific Anti-Tumor Necrosis Factor Agent: Korea versus Western
por: Seo, Hyungil, et al.
Publicado: (2016)

Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
por: Oh, Kyunghwan, et al.
Publicado: (2023)

Anti-tumor Necrosis Factor Therapy for Crohn Disease: Friend or Foe to the Surgeon?
por: Kim, Hungdai
Publicado: (2015)

The Long-Term Effect of Early Anti-Tumor Necrosis Factor on Restoration of Growth in Pediatric Crohn’s Disease
por: Shim, Jung Ok, et al.
Publicado: (2018)

Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy
por: Papamichael, Konstantinos, et al.
Publicado: (2017)

Are there interregional differences in the epidemiology and clinical characteristics of Crohn's disease in the Asia-Pacific region?
por: Lee, Sinwon, et al.
Publicado: (2016)

Predicting the future of anti-tumor necrosis factor therapy
por: Verweij, Cornelis L
Publicado: (2009)

Use of Vitamin D With Anti-Tumor Necrosis Factor Therapy for Crohn’s Disease
por: Bafutto, Mauro, et al.
Publicado: (2020)

Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls
por: Kotze, Paulo Gustavo, et al.
Publicado: (2017)

Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn’s Disease
por: Thurlapati, Aswani, et al.
Publicado: (2021)

Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study
por: Shin, Ju-Young, et al.
Publicado: (2021)

Tumor necrosis factor: is it time to change the name?
por: Pisetsky, David S
Publicado: (2014)

Long‐term outcomes of anti‐tumor necrosis factor therapy and surgery in nonperianal fistulizing Crohn's disease
por: Vuyyuru, Sudheer K, et al.
Publicado: (2021)

A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn’s Disease
por: Nie, Kai, et al.
Publicado: (2022)

Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
por: Moroi, Rintaro, et al.
Publicado: (2019)

Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn’s disease: a retrospective observational study
por: Park, Min Young, et al.
Publicado: (2021)

Pulmonary Tuberculosis After Therapy with Anti-Tumor Necrosis Factor (TNF) for Crohn Disease: A Case Report
por: da Silva, Douglas Inomata Cardoso, et al.
Publicado: (2021)

Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease
por: Vuyyuru, Sudheer K., et al.
Publicado: (2021)

Comparison of mucosa-associated microbiota in Crohn’s disease patients with and without anti-tumor necrosis factor-α therapy
por: Fukushima, Shinya, et al.
Publicado: (2022)

Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease
por: Netz, Uri, et al.
Publicado: (2017)

Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease
por: Buisson, Anthony, et al.
Publicado: (2022)

Changes of energy metabolism, nutritional status and serum cytokine levels in patients with Crohn’s disease after anti-tumor necrosis factor-α therapy
por: Nishida, Nao, et al.
Publicado: (2013)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

The Efficacy of Anti-Tumor Necrosis Factor Alpha for Symptomatic Stricturing Small Bowel Crohn’s Disease
por: Alourfi, Mansour, et al.
Publicado: (2020)

Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention
por: Pagnini, Cristiano, et al.
Publicado: (2021)

Risk factors for recurrence of Crohn's disease requiring surgery in patients receiving post-operative anti-tumor necrosis factor maintenance therapy
por: Araki, Toshimitsu, et al.
Publicado: (2018)

Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s disease
por: Li, Kangrong, et al.
Publicado: (2023)

Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
por: Lee, Ji Min, et al.
Publicado: (2022)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies
por: Bamberger, Sarah, et al.
Publicado: (2016)

Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease
por: Hiraoka, Sakiko, et al.
Publicado: (2018)

The Effect of Adiposity on Anti–Tumor Necrosis Factor-Alpha Levels and Loss of Response in Crohn's Disease Patients
por: Lim, Zixiang, et al.
Publicado: (2020)

Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy
por: Oh, Kyunghwan, et al.
Publicado: (2022)

Suspected de novo Hepatitis B in a Patient Receiving Anti-Tumor Necrosis Factor Alpha Therapy for the Treatment of Crohn's Disease
por: Ishida, Tetsuya, et al.
Publicado: (2014)

Practical strategy for optimizing the timing of anti-tumor necrosis factor-α therapy in Crohn disease: A nationwide population-based study
por: Kwak, Min Seob, et al.
Publicado: (2020)

SARS-CoV-2 infection in severe pediatric Crohn's disease. What about anti-tumor necrosis factor α therapy?
por: Bardasi, Giulia, et al.
Publicado: (2020)

Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn’s disease with poor prognostic factors
por: Oh, Eun Hye, et al.
Publicado: (2017)

Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn’s disease: correlation with SES-CD and clinical-biological markers
por: Stoppino, Luca Pio, et al.
Publicado: (2016)

Novel candidate drugs in anti-tumor necrosis factor refractory Crohn’s diseases: in silico study for drug repositioning
por: Kwak, Min Seob, et al.
Publicado: (2020)

Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn’s Disease
por: Kim, Sun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nhnujj9tmvso8vdl2n2mhoudki